Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration approved expanded U.S. Prescribing information for IZERVAY (avacincaptad pegol intravitreal ...
TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U ...
Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will "further [solidify] Izervay's status as a trusted choice for thousands of GA ...
Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago. These figures ...
IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the launch of Holibyâ„¢, a wellness brand offering scientifically formulated products for immune defense and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results